Mechanism of aspirin-induced inhibition on the secondary hyperalgesia in osteoarthritis model rats.
Acetylsalicylic acid
Immunology
Monosodium iodoacetate
Osteoarthritis
Pain research
Pharmaceutical science
Pharmacology
Rat model
Secondary hyperalgesia
Journal
Heliyon
ISSN: 2405-8440
Titre abrégé: Heliyon
Pays: England
ID NLM: 101672560
Informations de publication
Date de publication:
May 2020
May 2020
Historique:
received:
04
12
2019
revised:
24
04
2020
accepted:
06
05
2020
entrez:
2
6
2020
pubmed:
2
6
2020
medline:
2
6
2020
Statut:
epublish
Résumé
The daily activity of osteoarthritis (OA) patients is limited by chronic pain and central sensitization. Although non-steroidal anti-inflammatory drugs (NSAIDs) and acetaminophen are the first-line drugs for the treatment of OA-related pain, their efficacy on central sensitization remains unclear. In the present study, we evaluated the effect of acetylsalicylic acid (ASA, Aspirin) using an OA model induced by monosodium iodoacetate (MIA), which has a similar disease progression to human OA. Secondary hyperalgesia was assessed at the plantar surface of the hind paw by Von Frey test. We evaluated the expression of acid-sensing ion channel 3 (ASIC3) in dorsal root ganglia and that of tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) in the spinal cord, which may cause secondary hyperalgesia in OA, by immunohistochemical analysis and real-time qPCR. The administration of ASA attenuated secondary hyperalgesia at 1-3 weeks after MIA, while celecoxib, a selective cyclooxygenase (COX)-2 inhibitor, failed to attenuate secondary hyperalgesia at week 2 after MIA injection, suggesting that ASA exerts its analgesic effect through a COX-2-independent pathway. Immunohistochemical analysis of the dorsal root ganglia indicated that ASA reduced the expression of ASIC3 during OA progression. Expression of TNF-α mRNA, but not IL-1β mRNA, in the spinal cord following MIA injection was suppressed by ASA administration. These findings suggest that ASA may have the ability to attenuate secondary hyperalgesia through suppression of ASIC3 and/or TNF-α expression. ASA is therefore a clinically useful analgesic drug for treatment of secondary hyperalgesia in OA.
Identifiants
pubmed: 32478188
doi: 10.1016/j.heliyon.2020.e03963
pii: S2405-8440(20)30808-2
pii: e03963
pmc: PMC7248669
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e03963Informations de copyright
© 2020 The Authors.
Références
Pain. 2019 Apr;160(4):895-907
pubmed: 30585984
Maturitas. 2015 Jul;81(3):394-7
pubmed: 26027908
Atherosclerosis. 2004 Jun;174(2):207-13
pubmed: 15136050
J Biomed Sci. 2012 Aug 21;19:77
pubmed: 22909215
Ann Rheum Dis. 2010 May;69(5):903-9
pubmed: 19933746
BMC Complement Altern Med. 2018 Feb 20;18(1):69
pubmed: 29463254
Neurosci Lett. 2004 Nov 11;370(2-3):236-40
pubmed: 15488329
J Formos Med Assoc. 2011 Mar;110(3):145-52
pubmed: 21497277
N Engl J Med. 2010 Oct 14;363(16):1521-31
pubmed: 20942668
J Neurosci. 2001 Oct 15;21(20):8026-33
pubmed: 11588175
J Rheumatol. 1987 May;14 Spec No:130-1
pubmed: 3625668
J Neurosci. 2010 Mar 10;30(10):3752-61
pubmed: 20220009
J Neurosci Methods. 1995 Dec;63(1-2):55-9
pubmed: 8788048
Nat Rev Neurosci. 2013 Jul;14(7):461-71
pubmed: 23783197
J Anesth. 2016 Feb;30(1):55-63
pubmed: 26373954
Ann N Y Acad Sci. 2002 Jun;966:343-54
pubmed: 12114291
Pain. 2007 Apr;128(3):272-82
pubmed: 17276007
J Biol Chem. 2003 Dec 5;278(49):48907-13
pubmed: 14522957
Behav Brain Sci. 1997 Sep;20(3):404-19; discussion 435-513
pubmed: 10097003
J Neurophysiol. 2009 Sep;102(3):1551-9
pubmed: 19553487
Neurochem Res. 1998 Jun;23(6):919-22
pubmed: 9572681
Pharmacol Ther. 2010 Dec;128(3):549-58
pubmed: 20807551
Int J Mol Med. 2016 Dec;38(6):1922-1932
pubmed: 27748894
Arthritis Rheum. 1980 Jan;23(1):83-91
pubmed: 7352948
Arthritis Rheum. 2010 Oct;62(10):2995-3005
pubmed: 20556813
EXCLI J. 2017 Mar 14;16:265-277
pubmed: 28507472
Pain. 1986 Apr;25(1):125-32
pubmed: 3714284
Neurosci Lett. 2014 Mar 20;563:101-6
pubmed: 24495935
BMC Musculoskelet Disord. 2011 Jun 16;12:134
pubmed: 21679434
Nat Rev Rheumatol. 2016 Nov;12(11):632-644
pubmed: 27652499
Br J Pharmacol. 2011 Jan;162(1):72-83
pubmed: 20942867
Best Pract Res Clin Rheumatol. 2006 Feb;20(1):3-25
pubmed: 16483904
Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):20602-7
pubmed: 23185004
Mol Pain. 2011 Nov 17;7:88
pubmed: 22093915
Pain. 2008 Jul 31;137(3):662-9
pubmed: 18343037
Ann Rheum Dis. 2015 Jan;74(1):252-9
pubmed: 24152419
J Vet Med Sci. 2003 Nov;65(11):1195-9
pubmed: 14665748
Arthritis Care Res (Hoboken). 2011 Mar;63(3):320-7
pubmed: 20957660
Clin Rheumatol. 2010 May;29(5):451-5
pubmed: 20108016
Arthritis Rheum. 2008 Oct 15;59(10):1424-31
pubmed: 18821657